“…They also act as folliclestimulating hormone receptor agonists and muscarinic receptor 1 agonists. 22 To find novel organic DNase I inhibitors, in the current study 41 previously synthesized thiazolidinone derivatives, including twenty-six 2-alkylidene-4-oxothiazolidines (group A, 1-26) [23][24][25][26][27] (Table 1), four 2-alkylidene-4-oxothiazolidine S-oxides (group C, 38-41) 27 (Table 3), seven 6,7-dihydro-2Hthiazolo[3,2-a]pyridin-3(5H)-ones (group D, 42-48) 26 (Table 4), two 2-alkylidene-7a-methylhexahydro-2H-pyrano [2,3-d]thiazoles (group E, 49 and 50) 26 (Table 5), and two 4a-methyl-2,3,4,4a,7,8,9,10a-octahydropyrano[2′,3′:4,5]thiazolo[3,2-a]pyridines (group F, 52 and 53) 26 (Table 6), together with 12 newly synthesized thiazolidinone derivatives, including nine 2-alkylidene-4-oxothiazolidines (group A, 27-35) (Table 1), two 2,5-dialkylidene-4-oxothiazolidines (group B, 36 and 37) (Table 2), and one 2-alkylidene-7a-methylhexahydro-2H-pyrano [2,3-d]thiazole (group E, 51) (Table 5) were evaluated for inhibitory activity against bovine pancreatic DNase I in vitro. Those inhibiting the commercial DNase I with IC 50 values below 200 µM were further evaluated for inhibitory activity against DNase I in rat liver homogenate.…”